截至10月28日，禾元生物股东户数4.71万，较上期增加84075.00%；人均流通股869股，较上期减少 99.85%。2025年1月-9月，禾元生物实现营业收入1966.08万元，同比减少8.51%；归母净利润-1.21亿 元，同比减少8.44%。 责任编辑：小浪快报 融券方面，禾元生物1月27日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，武汉禾元生物科技股份有限公司位于湖北省武汉市武汉东湖新技术开发区神墩五路268号， 成立日期2006年11月16日，上市日期2025年10月28日，公司主营业务涉及运用水稻胚乳细胞重组蛋白表 达技术平台进行植物源人血清白蛋白等产品的研发、生产及销售。主营业务收入构成为：重组人白蛋白 75.44%，其他24.56%。 1月27日，禾元生物涨0.85%，成交额2.17亿元。两融数据显示，当日禾元生物获融资买入额1611.76万 元，融资偿还2512.54万元，融资净买入-900.78万元。截至1月27日，禾元生物融资融券余额合计2.62亿 元。 融资方面，禾元生物当日融资买入1611.7 ...

截至发稿，赵栩累计任职时间14年106天，现任基金资产总规模688.85亿元，任职期间最佳基金回报 233.59%， 任职期间最差基金回报-84.87%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 数据显示，工银瑞信基金旗下1只基金重仓禾元生物。工银科创ETF联接A（011614）四季度持有股数 1.65万股，占基金净值比例为0.02%，位居第五大重仓股。根据测算，今日浮盈赚取约1.15万元。连续3 天上涨期间浮盈赚取8.43万元。 工银科创ETF联接A（011614）成立日期2021年3月5日，最新规模14.94亿。今年以来收益13.15%，同类 排名53/335；近一年收益54.14%，同类排名42/209；成立以来收益19.7 ...

Group 1 - The core viewpoint of the news is that He Yuan Bio has shown a significant increase in stock price and trading activity, indicating positive market sentiment towards the company [1] - As of January 13, He Yuan Bio's stock price rose by 2.03% to 79.57 CNY per share, with a total market capitalization of 28.446 billion CNY [1] - The company has experienced a year-to-date stock price increase of 15.14%, with a 10.09% rise over the last five trading days and a 2.62% increase over the last 20 days [1] Group 2 - He Yuan Bio's main business involves the research, production, and sales of products using rice endosperm cell recombinant protein expression technology, with recombinant human albumin accounting for 75.44% of its revenue [1] - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, a significant increase of 84,075% compared to the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to shareholders of -121 million CNY, also a decrease of 8.44% year-on-year [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a slight decline in stock price and a notable change in financing activities on January 6, with a net financing buy of -2.01 million yuan [1] - On January 6, He Yuan Bio's financing buy amounted to 16.60 million yuan, while the financing repayment was 18.62 million yuan, resulting in a total financing balance of 237 million yuan, which represents 7.99% of its market capitalization [1] - The company specializes in the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with its main business revenue composition being 75.44% from recombinant human albumin and 24.56% from other products [1] Group 2 - As of October 28, the number of shareholders of He Yuan Bio reached 47,100, marking an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.66 million yuan, reflecting a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also down by 8.44% year-on-year [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a decline in stock price and trading volume, with significant net financing outflows on December 18, 2023 [1] - On December 18, He Yuan Bio's stock price fell by 0.33%, with a trading volume of 97.2 million yuan [1] - The financing data indicates that on the same day, the company had a financing buy-in of 9.9952 million yuan and a financing repayment of 13.3520 million yuan, resulting in a net financing outflow of 3.3569 million yuan [1] Group 2 - As of October 28, 2023, He Yuan Bio had 47,100 shareholders, an increase of 84,075% compared to the previous period [2] - The average number of circulating shares per shareholder was 869, which represents a decrease of 99.85% from the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to shareholders of -121 million yuan, a year-on-year decrease of 8.44% [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio has experienced fluctuations in stock price and trading volume, with a recent increase of 2.02% in its share price, reaching 80.64 CNY per share, while the total market capitalization stands at 28.829 billion CNY [1] - As of October 28, 2025, He Yuan Bio's main business involves the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with 75.44% of its revenue coming from recombinant human albumin [1][2] - The company has seen a significant increase in the number of shareholders, with a total of 47,100 shareholders as of October 28, representing an increase of 84,075% compared to the previous period [2] Group 2 - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million CNY, also a decrease of 8.44% year-on-year [2] - The stock has seen a decline of 11.48% year-to-date, with a recent 5-day increase of 2.71% and a 20-day decline of 31.60% [1] - The company operates within the pharmaceutical and biological industry, specifically in the blood products sector, and is categorized under several concepts including near-term new shares and innovative drugs [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a decline in financing net purchases and a decrease in revenue and net profit for the first nine months of 2025 [1][2] Group 2 - On November 25, He Yuan Bio's stock rose by 0.99%, with a trading volume of 361 million yuan [1] - The financing data on November 25 showed a financing purchase amount of 34.16 million yuan and a financing repayment of 64.34 million yuan, resulting in a net financing purchase of -30.18 million yuan [1] - As of November 25, the total balance of margin trading for He Yuan Bio was 313 million yuan, accounting for 9.87% of its circulating market value [1] Group 3 - As of October 28, the number of shareholders for He Yuan Bio was 47,100, an increase of 84,075% compared to the previous period [2] - The average circulating shares per person decreased to 869 shares, a reduction of 99.85% from the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.66 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, a year-on-year decrease of 8.44% [2]

Core Viewpoint - He Yuan Bio's stock price has experienced a decline of 4.23% year-to-date and 8.12% over the last five trading days, with significant trading activity noted in recent sessions [1][2]. Group 1: Stock Performance - On November 14, He Yuan Bio's stock rose by 2.06%, reaching 87.25 CNY per share, with a trading volume of 95.86 million CNY and a turnover rate of 2.69% [1]. - Year-to-date, He Yuan Bio's stock has dropped by 4.23%, and it has fallen by 8.12% in the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on November 7, where it recorded a net buy of -69.68 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million CNY, reflecting a year-on-year decrease of 8.51% [2]. - The company's net profit attributable to shareholders was -121 million CNY, a decline of 8.44% year-on-year [2]. Group 3: Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1].

Group 1 - The core viewpoint of the news is that He Yuan Bio has experienced a significant decline in stock price and financial performance, with a notable drop in trading activity and net outflow of funds [1][2]. Group 2 - As of November 12, He Yuan Bio's stock price increased by 2.33% to 88.00 CNY per share, with a trading volume of 1.16 billion CNY and a market capitalization of 31.46 billion CNY [1]. - The company has seen a net outflow of 11.32 million CNY in principal funds, with large orders showing a buy of 20.27 million CNY and a sell of 27.88 million CNY [1]. - Year-to-date, He Yuan Bio's stock price has decreased by 3.40%, and it has dropped 21.43% over the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on November 7, where it recorded a net buy of -69.68 million CNY [1]. Group 3 - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1]. Group 4 - He Yuan Bio belongs to the pharmaceutical and biological industry, specifically in the blood products sector, and is associated with concepts such as innovative drugs, newly listed stocks, biopharmaceuticals, and mid-cap stocks [2]. - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2]. - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million CNY, also down 8.44% year-on-year [2].

Core Insights - He Yuan Bio experienced a significant decline of 8.02% in stock price on November 11, with a trading volume of 9.52 billion yuan [1] - The company reported a net financing outflow of 16.81 million yuan on the same day, with a total financing and securities balance of 403 million yuan [1] Group 1: Financial Performance - For the period from January to September 2025, He Yuan Bio achieved a revenue of 19.66 million yuan, representing a year-on-year decrease of 8.51% [2] - The net profit attributable to the parent company was -121 million yuan, reflecting a year-on-year decline of 8.44% [2] Group 2: Shareholder and Market Data - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, an increase of 84,075% compared to the previous period [2] - The average number of circulating shares per shareholder decreased to 869 shares, down by 99.85% from the previous period [2] Group 3: Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice embryo cell recombinant protein expression technology [1] - The main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1]